Lanreotid Sun

Lanreotide, the active ingredient in Lanreotid Sun, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed to control hormone excess in conditions such as acromegaly and certain neuroendocrine tumors, reducing abnormal growth hormone and peptide secretion.

GNH USA supplies Lanreotid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring product integrity and timely delivery.

Lanreotide is used to manage disorders driven by excess secretion of growth hormone or peptide hormones. - Acromegaly: reduces elevated growth hormone levels and associated tissue overgrowth. - Neuroendocrine tumors (carcinoid): controls hormone‑related symptoms and may limit tumor progression. - Hormone‑secreting tumors: suppresses abnormal peptide hormone release, aiding symptom control.

Lanreotide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Injection site reactions: pain, erythema, or swelling at the subcutaneous site. - Gastrointestinal disturbances: nausea, abdominal pain, diarrhea, or constipation. - Gallbladder changes: biliary sludge or gallstones. - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients. - Headache: mild to moderate head pain. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain. - Severe allergic reactions: anaphylaxis, urticaria, or angioedema. - Cardiac arrhythmias: irregular heart rhythms reported in rare cases.

When prescribing Lanreotide, clinicians should consider several precautionary measures to ensure safe use. - Assess baseline hormone levels: evaluate growth hormone, IGF‑1, and relevant peptide concentrations before initiation. - Monitor glucose metabolism: check fasting glucose and HbA1c periodically, especially in patients with diabetes. - Evaluate gallbladder status: perform ultrasound if history of gallstones or biliary disease. - Review cardiac history: consider ECG monitoring in patients with known arrhythmias. - Adjust for renal or hepatic impairment: dose may need modification in severe organ dysfunction. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide plasma concentrations, raising risk of adverse effects. - Somatostatin receptor antagonists: can diminish therapeutic effect of lanreotide.

Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: lanreotide may alter glucose control, requiring dose adjustments. - Hormone replacement therapies: potential additive suppression of endogenous hormone secretion. - Anticoagulants: rare reports of altered bleeding risk; monitor coagulation parameters.